NTLA Share Price Performance
US$24.52
5.94 (31.97%)
28.1% undervalued intrinsic discount
US$34.08
Fair Value
Price US$24.52
AnalystConsensusTarget US$34.08
Fair ValueUS$34.08
Share PriceUS$24.52
28.1% undervalued intrinsic discount
Intellia Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 84 Fair Values set on narratives written by author
NTLA Community Narratives
AN
Fair Value US$34.08 28.2% undervalued intrinsic discount
Robust In Vivo CRISPR Trials Will Accelerate Therapeutic Success
1users have liked this narrative
0users have commented on this narrative
63users have followed this narrative
Recent NTLA News & Updates
Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Sep 18
Analysts Have Made A Financial Statement On Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) First-Quarter Report
May 11Industry Analysts Just Made An Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 10
Phase III Trials And Gene Editing Will Bring Promising Therapies
Strategic discontinuation of less promising programs and capital prioritization are expected to improve net margins and enhance commercial prospects.Intellia Therapeutics, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -4.47
- Gross Margin
- -732.63%
- Net Profit Margin
- -908.48%
- Debt/Equity Ratio
- 0%
Intellia Therapeutics, Inc. Competitors
Snowflake Analysis
About NTLA
- Founded
- 2014
- Employees
- 403
- CEO
- WebsiteView website
Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
U.S. Market Performance
- 7 Days: 0.3%
- 3 Months: 8.5%
- 1 Year: 17.3%
- Year to Date: 15.0%
In the last week, the market has been flat. Meanwhile, the market is actually up 17% over the past year. Earnings are forecast to grow by 15% annually. Market details ›